Pathways mediating VEGF-independent tumor angiogenesis

Coultas, 2005, Endothelial cells and VEGF in vascular development, Nature, 438, 937, 10.1038/nature04479 Risau, 1995, Vasculogenesis, Ann Rev Cell Dev Biol, 11, 73, 10.1146/annurev.cb.11.110195.000445 Folkman, 1995, Angiogenesis in cancer, vascular, rheumatoid and other disease, Nat Med, 1, 27, 10.1038/nm0195-27 Ferrara, 2002, VEGF and the quest for tumour angiogenesis factors, Nat Rev, 2, 795, 10.1038/nrc909 Ferrara, 2005, Angiogenesis as a therapeutic target, Nature, 438, 967, 10.1038/nature04483 Kerbel, 2008, Tumor angiogenesis, N Engl J Med, 358, 2039, 10.1056/NEJMra0706596 Nyberg, 2005, Endogenous inhibitors of angiogenesis, Cancer Res, 65, 3967, 10.1158/0008-5472.CAN-04-2427 Algire, 1945, Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants, J Natl Cancer Inst, 6, 73, 10.1093/jnci/6.1.73 Naumov, 2008, Tumor-vascular interactions and tumor dormancy, Apmis, 116, 569, 10.1111/j.1600-0463.2008.01213.x Gimbrone, 1972, Tumor dormancy in vivo by prevention of neovascularization, J Exp Med, 136, 261, 10.1084/jem.136.2.261 Almog, 2009, Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype, Cancer Res, 69, 836, 10.1158/0008-5472.CAN-08-2590 Ferrara, 2007, Targeting VEGF-A to treat cancer and age-related macular degeneration, Annu Rev Med, 58, 491, 10.1146/annurev.med.58.061705.145635 Ferrara, 2003, The biology of VEGF and its receptors, Nat Med, 9, 669, 10.1038/nm0603-669 Ferrara, 2004, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer, Nat Rev Drug Discov, 3, 391, 10.1038/nrd1381 Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med, 356, 125, 10.1056/NEJMoa060655 Bergers, 2008, Modes of resistance to anti-angiogenic therapy, Nat Rev, 8, 592, 10.1038/nrc2442 Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N Engl J Med, 356, 115, 10.1056/NEJMoa065044 Ellis, 2008, VEGF-targeted therapy: mechanisms of anti-tumour activity, Nat Rev, 8, 579, 10.1038/nrc2403 Chen, 2009, Antiangiogenic clinical strategies: adverse effects of anticancer agents that target the VEGF pathway, Nat Rev Clin Oncol, 10.1038/nrclinonc.2009.94 Ferrara, 2004, Vascular endothelial growth factor: basic science and clinical progress, Endocr Rev, 25, 581, 10.1210/er.2003-0027 Ebos, 2009, Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy, Clin Cancer Res, 15, 5020, 10.1158/1078-0432.CCR-09-0095 Coussens, 2002, Inflammation and cancer, Nature, 420, 860, 10.1038/nature01322 Orimo, 2006, Stromal fibroblasts in cancer: a novel tumor-promoting cell type, Cell Cycle, 5, 1597, 10.4161/cc.5.15.3112 Lin, 2007, A cytokine-mediated link between innate immunity, inflammation, and cancer, J Clin Invest, 117, 1175, 10.1172/JCI31537 Bendelac, 1997, Innate pathways that control acquired immunity, Curr Opin Immunol, 9, 1, 10.1016/S0952-7915(97)80151-3 Folkman, 1971, Tumor angiogenesis: therapeutic implications, N Engl J Med, 285, 1182, 10.1056/NEJM197111182852108 Gerhardt, 2003, VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia, J Cell Biol, 161, 1163, 10.1083/jcb.200302047 Gerber, 2000, Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor, Cancer Res, 60, 6253 Hida, 2005, A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities, Cancer Res, 65, 2507, 10.1158/0008-5472.CAN-05-0002 Morikawa, 2002, Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors, Am J Pathol, 160, 985, 10.1016/S0002-9440(10)64920-6 Baluk, 2003, Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors, Am J Pathol, 163, 1801, 10.1016/S0002-9440(10)63540-7 Lyden, 2001, Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth, Nat Med, 7, 1194, 10.1038/nm1101-1194 Nolan, 2007, Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization, Genes Dev, 21, 1546, 10.1101/gad.436307 Shaked, 2006, Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors, Science, 313, 1785, 10.1126/science.1127592 Shaked, 2009, Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents, Cancer Res, 10.1158/0008-5472.CAN-09-0381 Gothert, 2004, Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium, Blood, 104, 1769, 10.1182/blood-2003-11-3952 Purhonen, 2008, Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth, Proc Natl Acad Sci USA, 105, 6620, 10.1073/pnas.0710516105 Ferrara, 2009, Vascular endothelial growth factor, Arterioscler Thromb Vasc Biol, 29, 789, 10.1161/ATVBAHA.108.179663 Ferrara, 1997, The biology of vascular endothelial growth factor, Endocrine Rev, 18, 4, 10.1210/er.18.1.4 Ferrara, 1996, Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene, Nature, 380, 439, 10.1038/380439a0 Wang, 1995, Purification and characterization of hypoxia-inducible factor 1, J Biol Chem, 270, 1230, 10.1074/jbc.270.3.1230 Kim, 1993, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo, Nature, 362, 841, 10.1038/362841a0 Warren, 1995, Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis, J Clin Invest, 95, 1789, 10.1172/JCI117857 Presta, 1997, Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders, Cancer Res, 57, 4593 Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691 Sandler, 2006, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell-lung cancer, N Engl J Med, 355, 2542, 10.1056/NEJMoa061884 Miller, 2007, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, N Engl J Med, 357, 2666, 10.1056/NEJMoa072113 Holash, 2002, VEGF-Trap: a VEGF blocker with potent antitumor effects, Proc Natl Acad Sci USA, 99, 11393, 10.1073/pnas.172398299 Rini, 2006, Sorafenib, Expert Opin Pharmacother, 7, 453, 10.1517/14656566.7.4.453 Escudier, 2009, Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial, J Clin Oncol, 10.1200/JCO.2008.19.5511 Lang, 2008, FDA approves sorafenib for patients with inoperable liver cancer, Gastroenterology, 134, 379, 10.1053/j.gastro.2007.12.037 Smith, 2004, Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy, Oncol Res, 14, 175, 10.3727/000000003772462298 Broxterman, 2003, Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences, Drug Resist Updat, 6, 111, 10.1016/S1368-7646(03)00026-8 Shojaei, 2008, Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies, Drug Resist Updat, 11, 219, 10.1016/j.drup.2008.09.001 Shibuya, 2008, Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis, BMB Rep, 41, 278, 10.5483/BMBRep.2008.41.4.278 Holash, 1999, Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF, Science, 284, 1994, 10.1126/science.284.5422.1994 Rubenstein, 2000, Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption, Neoplasia, 2, 306, 10.1038/sj.neo.7900102 Yu, 2002, Effect of p53 status on tumor response to antiangiogenic therapy, Science, 295, 1526, 10.1126/science.1068327 Ince, 2005, Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab, J Natl Cancer Inst, 97, 981, 10.1093/jnci/dji174 Gerber, 2007, Mice expressing a humanized form of VEGF-A may provide insights into safety and efficacy of anti-VEGF antibodies, Proc Natl Acad Sci USA, 104, 3478, 10.1073/pnas.0611492104 Crawford, 2009, Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies, Trends Pharmacol Sci, 30, 624, 10.1016/j.tips.2009.09.004 Paez-Ribes, 2009, Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis, Cancer Cell, 15, 220, 10.1016/j.ccr.2009.01.027 Ebos, 2009, Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis, Cancer Cell, 15, 232, 10.1016/j.ccr.2009.01.021 Ebos, 2007, Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy, Proc Natl Acad Sci USA, 104, 17064, 10.1073/pnas.0708148104 Brahimi-Horn, 2007, Hypoxia and cancer, J Mol Med, 85, 1301, 10.1007/s00109-007-0281-3 Gerhardt, 2008, Pericytes: gatekeepers in tumour cell metastasis?, J Mol Med, 86, 135, 10.1007/s00109-007-0258-2 Gandhi, 2009, Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis, Cancer Prev Res (Phila Pa), 2, 330, 10.1158/1940-6207.CAPR-08-0213 Wolmark, 2009, A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP protocol C-08, J Clin Oncol, 27, 18s, 10.1200/jco.2009.27.18_suppl.lba4 Maglione, 1991, Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor, Proc Natl Acad Sci USA, 88, 9267, 10.1073/pnas.88.20.9267 Park, 1994, Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR, J Biol Chem, 269, 25646, 10.1016/S0021-9258(18)47298-5 de Vries, 1992, The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor, Science, 255, 989, 10.1126/science.1312256 Fischer, 2008, FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?, Nat Rev, 8, 942, 10.1038/nrc2524 Shalaby, 1995, Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice, Nature, 376, 62, 10.1038/376062a0 Waltenberger, 1994, Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor, J Biol Chem, 269, 26988, 10.1016/S0021-9258(18)47116-5 Fong, 1995, Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium, Nature, 376, 66, 10.1038/376066a0 Hiratsuka, 1998, Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice, Proc Natl Acad Sci USA, 4, 9349, 10.1073/pnas.95.16.9349 Davis-Smyth, 1996, The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade, EMBO J, 15, 4919, 10.1002/j.1460-2075.1996.tb00872.x Ferrara, 1998, Vascular endothelial growth factor is essential for corpus luteum angiogenesis, Nat Med, 4, 336, 10.1038/nm0398-336 Gerber, 1999, VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation, Nat Med, 5, 623, 10.1038/9467 Hiratsuka, 2001, Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis, Cancer Res, 61, 1207 Kerber, 2008, Flt-1 signaling in macrophages promotes glioma growth in vivo, Cancer Res, 68, 7342, 10.1158/0008-5472.CAN-07-6241 Wu, 2006, Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer, Clin Cancer Res, 12, 6573, 10.1158/1078-0432.CCR-06-0831 Hiratsuka, 2002, MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis, Cancer Cell, 2, 289, 10.1016/S1535-6108(02)00153-8 Murakami, 2006, Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocyte/macrophages, Blood, 108, 1849, 10.1182/blood-2006-04-016030 Dawson, 2009, VEGFR1-activity-independent metastasis formation, Nature, 461, E4, 10.1038/nature08254 Batchelor, 2007, AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients, Cancer Cell, 11, 83, 10.1016/j.ccr.2006.11.021 Motzer, 2006, Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma, J Clin Oncol, 24, 16, 10.1200/JCO.2005.02.2574 Fischer, 2007, Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels, Cell, 131, 463, 10.1016/j.cell.2007.08.038 Shojaei, 2007, Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells, Nat Biotechnol, 25, 911, 10.1038/nbt1323 Casanovas, 2005, Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors, Cancer Cell, 8, 299, 10.1016/j.ccr.2005.09.005 Alitalo, 2005, Lymphangiogenesis in development and human disease, Nature, 438, 946, 10.1038/nature04480 Tammela, 2008, Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation, Nature, 454, 656, 10.1038/nature07083 Neufeld, 2002, The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis, Trends Cardiovasc Med, 12, 13, 10.1016/S1050-1738(01)00140-2 Pan, 2007, Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth, Cancer Cell, 11, 53, 10.1016/j.ccr.2006.10.018 Yuan, 2002, Abnormal lymphatic vessel development in neuropilin 2 mutant mice, Development, 129, 4797, 10.1242/dev.129.20.4797 Karpanen, 2006, Functional interaction of VEGF-C and VEGF-D with neuropilin receptors, Faseb J, 20, 1462, 10.1096/fj.05-5646com Caunt, 2008, Blocking neuropilin-2 function inhibits tumor cell metastasis, Cancer Cell, 13, 331, 10.1016/j.ccr.2008.01.029 Beenken, 2009, The FGF family: biology, pathophysiology and therapy, Nat Rev Drug Discov, 8, 235, 10.1038/nrd2792 Bikfalvi, 1997, Biological roles of fibroblast growth factor-2, Endocr Rev, 18, 26, 10.1210/er.18.1.26 Cao, 2008, R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways, J Mol Med, 86, 785, 10.1007/s00109-008-0337-z Dufraine, 2008, Notch signaling regulates tumor angiogenesis by diverse mechanisms, Oncogene, 27, 5132, 10.1038/onc.2008.227 Siekmann, 2008, Modulation of VEGF signalling output by the Notch pathway, Bioessays, 30, 303, 10.1002/bies.20736 Siekmann, 2007, Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries, Nature, 445, 781, 10.1038/nature05577 Hellstrom, 2007, Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis, Nature, 445, 776, 10.1038/nature05571 Mailhos, 2001, Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis, Differentiation, 69, 135, 10.1046/j.1432-0436.2001.690207.x Noguera-Troise, 2006, Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis, Nature, 444, 1032, 10.1038/nature05355 Ridgway, 2006, Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis, Nature, 444, 1083, 10.1038/nature05313 Dong, 2004, VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis, EMBO J, 23, 2800, 10.1038/sj.emboj.7600289 Liang, 2006, Cross-species vegf-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal vegf, J Biol Chem, 281, 951, 10.1074/jbc.M508199200 Tejada, 2006, Tumor-driven paracrine PDGF receptor—a signaling is a key determinent of stromal cell recruitment in a model of human lung carcinoma, Clin Cancer Res, 12, 2676, 10.1158/1078-0432.CCR-05-1770 Orimo, 2005, Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion, Cell, 121, 335, 10.1016/j.cell.2005.02.034 Olumi, 1999, Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium, Cancer Res, 59, 5002 Loeffler, 2006, Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake, J Clin Invest, 116, 1955, 10.1172/JCI26532 Crawford, 2009, PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment, Cancer Cell, 15, 21, 10.1016/j.ccr.2008.12.004 di Tomaso, 2009, PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment, PLoS ONE, 4, e5123, 10.1371/journal.pone.0005123 Anderberg, 2009, Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts, Cancer Res, 69, 369, 10.1158/0008-5472.CAN-08-2724 Pietras, 2008, Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting, PLoS Med, 5, e19, 10.1371/journal.pmed.0050019 Balkwill, 2001, Inflammation and cancer: back to Virchow?, Lancet, 357, 539, 10.1016/S0140-6736(00)04046-0 Mantovani, 2008, Tumour immunity: effector response to tumour and role of the microenvironment, Lancet, 371, 771, 10.1016/S0140-6736(08)60241-X De Palma, 2005, Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors, Cancer Cell, 8, 211, 10.1016/j.ccr.2005.08.002 De Palma, 2007, Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications, Trends Immunol, 28, 519, 10.1016/j.it.2007.09.004 Shojaei, 2008, Role of myeloid cells in tumor angiogenesis and growth, Trends Cell Biol, 18, 372, 10.1016/j.tcb.2008.06.003 Serafini, 2006, Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression, Semin Cancer Biol, 16, 53, 10.1016/j.semcancer.2005.07.005 Diaz-Montero, 2009, Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy, Cancer Immunol Immunother, 58, 49, 10.1007/s00262-008-0523-4 Marigo, 2008, Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells, Immunol Rev, 222, 162, 10.1111/j.1600-065X.2008.00602.x Yang, 2004, Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis, Cancer Cell, 6, 409, 10.1016/j.ccr.2004.08.031 Mollay, 1999, Bv8, a small protein from frog skin and its homologue from snake venom induce hyperalgesia in rats, Eur J Pharmacol, 374, 189, 10.1016/S0014-2999(99)00229-0 LeCouter, 2001, Identification of an angiogenic mitogen selective for endocrine gland endothelium, Nature, 412, 877, 10.1038/35091000 Li, 2001, Identification of two Prokineticin cDNAs: recombinant proteins potently contract gestrointestinal smooth muscle, Mol Pharmacol, 59, 692, 10.1124/mol.59.4.692 LeCouter, 2004, Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization, Proc Natl Acad Sci USA, 101, 16813, 10.1073/pnas.0407697101 Shojaei, 2008, Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression, Proc Natl Acad Sci USA, 105, 2640, 10.1073/pnas.0712185105 Shojaei, 2007, Bv8 regulates myeloid cell-dependent tumour angiogenesis, Nature, 450, 825, 10.1038/nature06348 Shojaei, 2009, G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models, Proc Natl Acad Sci USA, 106, 6742, 10.1073/pnas.0902280106 Nozawa, 2006, Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis, Proc Natl Acad Sci USA, 103, 12493, 10.1073/pnas.0601807103 Zhong, 2009, Characterization and regulation of Bv8 in human blood cells, Clin Cancer Res, 15, 2675, 10.1158/1078-0432.CCR-08-1954